Beyond Single Genes: The Polygenic Revolution
For many years, genetic medicine focused on rare, high-impact mutations in single genes — the kind that cause Huntington's disease, BRCA-related breast cancer risk, or cystic fibrosis. But for the most common conditions affecting people — heart disease, type 2 diabetes, schizophrenia, obesity — there is no single "bad gene." Instead, risk is shaped by thousands of tiny genetic differences spread across the genome, each contributing a small push in one direction or another.
This is where polygenic risk scores (PRS) come in — and they represent one of the most active and debated frontiers in genomic medicine today.
What Is a Polygenic Risk Score?
A polygenic risk score is a number that summarizes the estimated genetic contribution to a person's risk for a particular disease or trait. It is calculated by:
- Identifying relevant variants: Large-scale genome-wide association studies (GWAS) scan hundreds of thousands of people's genomes to find genetic variants (usually SNPs) that are statistically associated with a disease.
- Weighting each variant: Each associated SNP is assigned a weight based on the strength of its association — how much each copy of the risk allele increases or decreases risk.
- Summing across the genome: The individual's alleles at all relevant SNP positions are tallied, weighted, and summed to produce a single score.
The result places a person somewhere on a distribution — typically compared to the average of the population. Those at the high end of the distribution face meaningfully higher risk; those at the low end, lower risk.
What Conditions Can PRS Be Applied To?
PRS have been developed for a wide range of conditions, including:
- Coronary artery disease
- Type 2 diabetes
- Breast, prostate, and colorectal cancer
- Atrial fibrillation
- Schizophrenia and bipolar disorder
- Age-related macular degeneration
For coronary artery disease in particular, research has shown that individuals in the top few percent of polygenic risk score distributions have risk levels comparable to those with single-gene disorders like familial hypercholesterolemia — a finding with potentially significant clinical implications.
How Accurate Are Polygenic Risk Scores?
This is the central debate. PRS have clear population-level predictive value, meaning that at the extremes of the distribution, they can meaningfully stratify risk. But at the individual level, they are far from deterministic:
- Most common diseases are caused by a complex interplay of genetics, environment, lifestyle, and chance. A high PRS does not mean disease is inevitable.
- Current PRS are built primarily from data on people of European ancestry, which limits their accuracy and fairness when applied to people of other ancestries — an urgent equity problem the field is working to address.
- The variants included in most PRS together explain only a portion of the known heritability of most complex diseases (the so-called "missing heritability" problem).
Clinical and Ethical Implications
Several potential uses of PRS in healthcare are being studied:
- Enhanced screening programs: Directing mammography or colonoscopy resources toward those at highest genetic risk.
- Preventive treatment: Initiating statins or other preventive therapies earlier in high-PRS individuals for heart disease.
- Drug development: Using PRS to identify trial participants most likely to benefit from a given therapy.
However, concerns exist around psychological impact (how people respond to learning they have a high score), the risk of false reassurance for those with low scores who still have significant environmental risk, and the potential for PRS to be misused in insurance or employment decisions.
The Road Ahead
Polygenic risk scores are becoming more powerful as GWAS datasets grow larger and more diverse, and as methods for combining PRS with clinical and environmental data improve. The vision for the future is precision prevention — using a person's full genomic profile, alongside their medical history and lifestyle, to deliver genuinely personalized risk assessments and preventive strategies. The science is advancing rapidly, but careful clinical validation and equitable implementation remain essential next steps.